faCellitate

Executive Summary

faCellitate is a German biotechnology company specializing in advanced cell culture tools for 3D spheroid formation, a critical technique in cell therapy and regenerative medicine. Founded in 2017 and based in Stuttgart, the company's flagship product, BIOFLOAT™ plates, are ultra-low attachment surfaces recommended as top performers for spheroid generation. A recent study by the Karolinska Institute validated BIOFLOAT™ plates for primary human and canine hepatocyte spheroid formation, highlighting their relevance in liver research and drug toxicity testing. By enabling more physiologically relevant 3D cell models, faCellitate addresses the growing demand for improved in vitro systems in pharmaceutical R&D and academic research. While the company remains private with limited disclosed funding or valuation, its technology is well-regarded in specialized publications, suggesting a strong niche position. The market for 3D cell culture is expanding as the industry shifts away from 2D models, positioning faCellitate to capture opportunities in drug discovery, toxicology, and personalized medicine. However, the small size and lack of commercial details temper conviction.

Upcoming Catalysts (preview)

• Q3 2026Publication of new validation studies in peer-reviewed journals expanding BIOFLOAT™ applications70% success
• Q4 2026Partnership or distribution agreement with major life science reagents supplier40% success
• Q1 2027Launch of complementary product line (e.g., 3D culture medium or assay kits)50% success